Form 4: BioAtla Director Scott Smith Granted 23,500 Restricted Stock Units

BioAtla, Inc. Director Scott Andrew Smith was granted 23,500 shares of common stock in the form of a time-based restricted stock unit award, vesting in 2026 or at the next annual meeting.

Summary

• Scott Andrew Smith, a Director of BioAtla, Inc. (BCAB), was granted 23,500 shares of common stock.
• The grant is in the form of a time-based Restricted Stock Unit (RSU) award.
• The RSU award will vest 100% on the earlier of June 18, 2026, or the next Company annual meeting of stockholders.
• Vesting is contingent upon Mr. Smith's continued service through the vesting date.
• Following this transaction, Mr. Smith beneficially owns 321,550 shares of common stock directly.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued alignment of a director's interests with the company's long-term performance and serves as a retention mechanism, which is generally viewed favorably.

Positives

• The grant of 23,500 Restricted Stock Units to Director Scott Andrew Smith serves as an incentive for continued service and aligns his interests with long-term shareholder value.
• The RSU award, vesting over time, contributes to the retention of key board members.

Future Outlook

The RSU award is structured to vest on the earlier of June 18, 2026, or the next Company annual meeting of stockholders, subject to the director's continued service, indicating a future commitment and retention strategy.

Industry Context

This Form 4 filing represents a routine insider transaction, specifically an equity grant to a director, which is a common practice in the biotechnology and pharmaceutical industries for executive and board compensation and retention.

Related Party Transactions

• The grant of Restricted Stock Units to Director Scott Andrew Smith constitutes a related party transaction, as it involves an equity award from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of the RSUs, but also benefit from the retention and alignment of a director's interests with the company's long-term performance.
• Employees: No direct impact mentioned, but reflects standard compensation practices for leadership.
• Director (Scott Andrew Smith): Receives additional equity compensation, increasing his beneficial ownership and aligning his financial interests with the company's stock performance.

Next Steps

• Vesting of the 23,500 Restricted Stock Units on the earlier of June 18, 2026, or the next Company annual meeting of stockholders, contingent on continued service.

Key Dates

Keywords

BioAtla, BCAB, Form 4, SEC filing, Restricted Stock Unit, RSU, insider transaction, equity award, director compensation, stock grant